Swiss drugmaker Novartis has revealed fresh plans to slim down its workforce, with a further 680 US and Swiss jobs to be cut from its development organizational 10 April 2024
Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024
Seaport Therapeutics has become the latest founded entity to be created by PureTech Health, the UK biotech behind Karuna Therapeutics, which was recently acquir 9 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.